-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $49

Benzinga·09/09/2026 16:15:20
语音播报
Truist Securities analyst Alexander Xenakis maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $58 to $49.